Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

New chemical classes of preclinical compounds identified for Alzheimer’s disease

In an announcement today, Mount Sinai School of Medicine and Medisyn Technologies, Inc. said they have identified new chemical classes of preclinical compounds that may eventually lead to the first effective management of toxic amyloid aggregation and accumulation in the brain— an abnormal biological process long suspected by many researchers to be a major culprit in the onset and progression of Alzheimer’s disease.

4 Mar 2010

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.

3 Mar 2010

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.

3 Mar 2010

Axiogenesis, Lonza Cologne announce global distribution agreement

Axiogenesis AG has entered into a worldwide, exclusive distribution agreement with Lonza Cologne AG effective 01 January 2010. The agreement includes Axiogenesis’s current product and service portfolio, including the industry standard Cor.At® mouse embryonic stem cell-derived cardiomyocytes.

3 Mar 2010

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with Harvard University and the Howard Hughes Medical Institute to provide their researchers with the LEAP™ Cell Processing Workstation.

3 Mar 2010

AB SCIEX launches mass-spectrometry-based software application to advance lipid biomarker research

AB SCIEX, a global leader in life science analytical technologies, today announced the launch of the first mass-spectrometry-based software application specifically designed to advance the study of lipidomics.

3 Mar 2010

Agilent Technologies announces new lab informatics suite at Pittcon 2010

Agilent’s major new lab informatics suite, the OpenLAB portfolio, is designed to enable customers to easily capture, analyze and share scientific data throughout the lab and across the enterprise. OpenLAB is scalable, open architecture based on industry open standards.

2 Mar 2010

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

Pangu BioPharma's naturally occurring splice variants of human tRNA synthetases study awarded second grant

The Innovation and Technology Commission of the Hong Kong government has awarded Pangu BioPharma, the Hong Kong subsidiary of aTyr Pharma, a second grant to fund research it is performing in collaboration with the Hong Kong University of Science and Technology (HKUST). The Innovation and Technology Fund (ITF) provides matching funds over the next 18 months to expand Pangu's successful work in the identification and characterization of naturally occurring splice variants of human tRNA synthetases.

1 Mar 2010

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and materials and have been evaluated based on business model, strategies for deploying and scaling up its technologies and the likelihood of success. Each company in the 2010 TR50 has excelled not only at inventing technology but also at using it to transform how we live and work.

26 Feb 2010

Librede to develop technologies for improving ion channel drug discovery and screening at CNSI incubator

Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.

26 Feb 2010

Caliper Life Sciences files patent infringement lawsuit against Carestream Health

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, and its wholly owned subsidiary Xenogen Corporation, today announced the filing of a patent infringement lawsuit in the U.S. District Court for the Eastern District of Texas.

25 Feb 2010

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.

25 Feb 2010

Unique technology identifies drug candidates, speeds up drug development

The search for new therapeutic agents is time-consuming and expensive. Pharmaceutical companies may have to screen thousands of compounds for the ability to bind a target molecule before they hit upon a promising drug candidate.

From NanoTemper Technologies 24 Feb 2010

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.

24 Feb 2010

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

WuXi PharmaTech (WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it received the formal certificate of GMP compliance from the Medical Products Agency (MPA) of Sweden, acting on behalf of the European Medicines Agency (EMEA), for its c-GMP drug product manufacturing and analytical testing facilities located in Shanghai.

24 Feb 2010

Lilly, Merck, Pfizer collaborate to accelerate research on commonly-diagnosed cancer

Eli Lilly and Company, Merck (also known as Merck Sharp & Dohme (MSD) outside the USA and Canada), and Pfizer Inc. today announced the formation of the Asian Cancer Research Group, Inc., an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia.

23 Feb 2010

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's facility meets the highest standards of animal care and research practices.

22 Feb 2010

Caliper Life Sciences forms SAB to develop additional solutions for next generation sequencing workflows

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced the formation of a scientific advisory board to guide its efforts in automated sample preparation for next generation and third generation sequencing platforms. Caliper worked closely with leading genome centers to develop the LabChip® XT, which was announced today, and is now expanding its efforts to develop additional solutions for next generation sequencing workflows.

22 Feb 2010

$Caliper Life Sciences introduces automated nucleic acid fractionation instrument, LabChip XT$

Caliper Life Sciences introduces automated nucleic acid fractionation instrument, LabChip XT

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced the LabChip XT, an automated nucleic acid fractionation instrument.

19 Feb 2010

Drug Discovery News and Research

Further Reading

New chemical classes of preclinical compounds identified for Alzheimer’s disease

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

Axiogenesis, Lonza Cologne announce global distribution agreement

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

AB SCIEX launches mass-spectrometry-based software application to advance lipid biomarker research

Agilent Technologies announces new lab informatics suite at Pittcon 2010

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Pangu BioPharma's naturally occurring splice variants of human tRNA synthetases study awarded second grant

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Librede to develop technologies for improving ion channel drug discovery and screening at CNSI incubator

Caliper Life Sciences files patent infringement lawsuit against Carestream Health

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

Unique technology identifies drug candidates, speeds up drug development

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

Lilly, Merck, Pfizer collaborate to accelerate research on commonly-diagnosed cancer

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

Caliper Life Sciences forms SAB to develop additional solutions for next generation sequencing workflows

Caliper Life Sciences introduces automated nucleic acid fractionation instrument, LabChip XT

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News